Susan Serrao

Yang Z1, Bedugnis A1, Levinson S2, DiNubile M2, Stossel T2, Lu Q1, Kobzik L1.November 6, 2019 Abstract Background: Host-derived inflammatory responses contribute to the morbidity and mortality of severe influenza, suggesting that immunomodulatory therapy may improve outcomes. The normally circulating protein, human plasma gelsolin, is available in recombinant form (rhu-pGSN) and has beneficial effects in a variety of pre-clinical models of inflammation […]

Yang Z1, Bedugnis A1, Levinson S2, Dinubile M2, Stossel T2, Lu Q1, Kobzik L1.September 26, 2019 Abstract Therapy to enhance host immune defenses may improve outcomes in serious infections, especially for antibiotic-resistant pathogens. Recombinant human plasma gelsolin (rhu-pGSN), a normally circulating protein, has beneficial effects in diverse preclinical models of inflammation and injury. We evaluated delayed therapy (24-48 hours after challenge)

Ordija CM1, Chiou TT1,2, Yang Z1, Deloid GM1, de Oliveira Valdo M1, Wang Z1, Bedugnis A1, Noah TL3, Jones S4, Koziel H5, Kobzik L6.June 1, 2017 Abstract Lung injury can release intracellular actin into the alveolar milieu and is also associated with increased susceptibility to secondary infections. We investigated the effect of free (extracellular) actin on lung macrophage host defense functions. Western blot analysis demonstrated

Yang Z1, Chiou TT2, Stossel TP3, Kobzik L4.June 1, 2017 Abstract Plasma gelsolin (pGSN) functions as part of the “extracellular actin-scavenging system,” but its potential to improve host defense against infection has not been studied. In a mouse model of primary pneumococcal pneumonia, recombinant human pGSN (rhu-pGSN) caused enhanced bacterial clearance, reduced acute inflammation, and improved survival. In

Li-feng Huang, Yong-ming Yao, Jin-feng Li, Ning Dong, Chen Liu,Yan Yu, Li-xin He, Zhi-yong ShengNovember 1, 2011 Abstract Background Depletion of the circulating actin-binding protein, plasma gelsolin (pGSN) has been described in critically ill surgical patients. We hypothesized that the extent of pGSN reduction might correlate with different outcome of burn patients. The study was

Patricia A. Rothenbach, Benny Dahl, Jason J. Schwartz, Grant E. O’Keefe, Masaya Yamamoto, William M. Lee, Jureta W. Horton, Helen L. Yin, and Richard H. TurnageJanuary 1, 2004 Abstract Reduced plasma concentrations of the extracellular actin-binding proteins gelsolin and Gc-globulin correlate with pulmonary failure and death in humans after injury. The purpose of this study was to investigate the role of plasma gelsolin

Christofidou-Solomidou M1, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ.January, 2002 Abstract BACKGROUND: The acute respiratory distress syndrome remains a common and poorly understood complication of a variety of insults. Ventilation with high concentrations of inspired oxygen may further damage already compromised lungs. By scavenging extracellular actin and modulating the effects of lysophosphatidic acid, plasma gelsolin could

YL Hu*, H Li*, WH Li, HX Meng, YZ Fan, WJ Li, YT Ji, H Zhao, L Zhang, XM Jin, FM ZhangFM ZhangOctober 11, 2013 Abstract Plasma gelsolin, the extracellular gelsolin isoform, circulates in the blood of healthy individuals at a concentration of 200 ± 50 mg/l and plays important roles in the extracellular actin-scavenging system during tissue damage. Decreased plasma gelsolin levels have been observed in many

Osborn TM1, Dahlgren C, Hartwig JH, Stossel TP.April, 2007 Abstract Gelsolin is a highly conserved intracellular actin-binding protein with an extracellular isoform, plasma gelsolin (pGSN). Blood concentrations of pGSN decrease in response to diverse tissue injuries. Depletion of pGSN to critical levels precedes and often predicts complications of injuries such as lung permeability changes and death. Administration of

Lee PS1, Sampath K, Karumanchi SA, Tamez H, Bhan I, Isakova T, Gutierrez OM, Wolf M, Chang Y, Stossel TP, Thadhani R.May, 2009 Abstract Plasma gelsolin (pGSN) binds actin and bioactive mediators to localize inflammation. Low pGSN correlates with adverse outcomes in acute injury, whereas administration of recombinant pGSN reduces mortality in experimental sepsis. We found that mean pGSN levels of 150 patients randomly selected